{"filings":[{"id":99264,"accession_number":"0001193125-26-214569","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"NYSE American accepts Cryo-Cell compliance plan; trading continues through Sep 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice of non-compliance on Mar 12, 2026 for stockholders' deficit and net losses in two of three fiscal years ending Nov 30, 2025.","Compliance plan accepted May 6, 2026; plan period extends to September 9, 2027 to regain listing standards.","Common stock remains listed and traded on NYSE American during plan period, subject to periodic review.","Failure to regain compliance or make progress by deadline could result in delisting proceedings.","Company reported stockholders' deficit as of Nov 30, 2025 and net losses in FY2023, FY2024, FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115149,"accession_number":"0001193125-26-104392","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Cryo-Cell receives NYSE American delisting notice over stockholders' deficit and net losses","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American cited stockholders' deficit as of Nov 30, 2025 and net losses in two of three fiscal years ended Nov 30, 2025.","Company must submit compliance plan by April 8, 2026; if accepted, extension up to 18 months possible.","Trading of CCEL common stock continues on NYSE American while company pursues compliance plan.","No assurance that plan will be accepted or that compliance can be regained; delisting possible if not."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131556,"accession_number":"0001193125-25-277872","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cryo-Cell International suspends Q4 2025 dividend; future payouts uncertain","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Company will not declare a quarterly cash dividend for Q4 fiscal 2025.","Decision driven by financial performance, capital requirements, and strategic priorities.","No commitment to future dividends; each quarter's decision will be evaluated separately.","Announced on November 12, 2025 via Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131555,"accession_number":"0001193125-25-248883","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cryo-Cell International amends credit agreement; reduces revolver to $8M, extends maturities to 2027/2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fifth Amendment extends RCF maturity to Oct 2027 and Term Loan maturity to Jul 2032.","Revolving credit commitment reduced from $10M to $8M; subsidiary Celle Corp. added as guarantor.","Applicable margins revised: Base Rate +4.25% (Term), +3.75% (Revolver); SOFR +3.25% (Term), +2.75% (Revolver); commitment fee 0.25%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148130,"accession_number":"0001193125-25-200170","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cryo-Cell sets 2025 annual meeting for Oct 21; record date Sept 15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting scheduled for October 21, 2025.","Record date for voting is September 15, 2025.","Stockholder proposals and director nominations must be submitted by September 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166890,"accession_number":"0000950170-25-076433","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Duke terminates patent license with Cryo-Cell effective May 17; Cryo-Cell previously sought arbitration","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Duke University terminated Patent and Technology License Agreement effective May 17, 2025, claiming Cryo-Cell breached.","Cryo-Cell had previously filed a demand for arbitration against Duke, alleging fraudulent inducement and breach.","The license granted Cryo-Cell exclusive rights to commercialize certain products and processes for human disease treatment.","Termination could impact Cryo-Cell's ability to commercialize the licensed technology; arbitration is ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166889,"accession_number":"0000950170-25-067147","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryo-Cell reduces quarterly dividend to $0.15 per share, payable May 30, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board declares reduced quarterly cash dividend of $0.15 per share, citing current economic environment and capital allocation alternatives.","Dividend payable May 30, 2025 to shareholders of record as of May 21, 2025.","Board may change dividend policy at any time; no assurance of future dividends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200887,"accession_number":"0000950170-24-119642","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cryo-Cell International reports annual meeting vote results; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors David Portnoy, Harold Berger, Mark Portnoy, and Daniel Mizrahi each elected with For votes ranging from 3.6M to 4.1M.","Ratification of WIPFLI LLC as independent auditor passed: 6,697,620 For vs 186 Against.","Non-binding advisory resolution on executive compensation approved: 4,152,942 For, 287,390 Against.","Authorization to vote on other business passed with 3,571,034 For, 855,538 Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200886,"accession_number":"0000950170-24-118607","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryo-Cell initiates $0.25 quarterly cash dividend, payable Nov 29, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend of $0.25 per share declared for common stock.","Record date: November 15, 2024; payment date: November 29, 2024.","Chairman David Portnoy says dividend does not detract from ongoing strategic alternatives review.","Board will evaluate policy regularly and may increase, decrease, or suspend dividends based on earnings and cash flows."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200885,"accession_number":"0000950170-24-115106","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryo-Cell Q3 revenue $8.07M, net income $1.05M; strategic review ongoing, spinoff on hold","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.07M vs $7.87M YoY; net income $1.05M ($0.13/diluted) vs $0.68M ($0.08).","Gains on marketable securities $522k vs $93k YoY, boosting earnings.","Company exploring strategic alternatives to maximize shareholder value; process ongoing.","Spinoff of Celle Corp on hold due to arbitration demand with Duke University (see Form 10-Q).","Board considering instituting regular quarterly dividend; no decision yet."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":23961761.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216880,"accession_number":"0000950170-24-107340","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cryo-Cell sets 2024 annual meeting for Oct 29; record date Sep 20","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting of Stockholders scheduled for October 29, 2024.","Record date for voting eligibility fixed as September 20, 2024.","Stockholder proposals or director nominations due within 10 days of Sep 17 public disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254250,"accession_number":"0000950170-24-036165","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cryo-Cell plans spin-off of Celle Corp. and explores strategic alternatives including sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized spin-off of newly formed Celle Corp. via stock dividend to Cryo-Cell shareholders.","Spin-off expected in Q2 or Q3 2024; Celle Corp. holds Duke University license and other assets.","Company will explore equity/debt financings or possible sale/merger for post-spin-off Cryo-Cell.","No assurance that any transaction will occur; further details to be disclosed in SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271733,"accession_number":"0000950170-23-053122","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cryo-Cell International annual meeting: all director nominees elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees elected: David Portnoy (3.1M for), Harold Berger (3.1M), Mark Portnoy (3.1M), Daniel Mizrahi (3.2M).","Ratification of WIPFLI LLC as independent auditor for FY 2023: 6.3M for, 159k against.","Non-binding advisory resolution on named executive officer compensation approved: 3.0M for, 365k against.","Authorization to vote proxies on other business passed: 3.1M for, 410k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288582,"accession_number":"0001193125-23-221510","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cryo-Cell sets 2023 annual meeting for Oct 10; record date Sept 5","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting date: October 10, 2023. Record date for voting: September 5, 2023.","Stockholder proposal/nomination deadline is 10 calendar days after August 25 public disclosure.","Deadline falls on September 4, 2023 for both business and director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327899,"accession_number":"0000950170-23-007079","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cryo-Cell amends Duke license, adds milestone for autism MSC therapy; funds IMPACT study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment removes final license fee payment to Duke; license fee now paid in full.","New milestone payment triggered upon FDA approval of first cord tissue MSC product for autism spectrum disorder.","New milestone requires Cryo-Cell to open manufacturing facility for licensed product before Phase III trial initiation.","Cryo-Cell entered Research Agreement to fund Duke IMPACT Study; 14 monthly payments starting April 2023.","IMPACT Study targeted accrual reached: 137 patients; draft publication due no later than September 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345570,"accession_number":"0000950170-22-027095","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cryo-Cell enters new 2-year employment agreements with co-CEOs; base salaries set at $700K and $540K","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Portnoy base salary $700K; Mark Portnoy base salary $540K; effective Dec 1, 2022.","Signing option grants: 50K shares (David) and 25K shares (Mark), exercisable only if stock closes above $8.00.","Severance for involuntary termination or resignation for good reason: 2x base salary plus average of recent bonuses, paid over 3 years.","David Portnoy's principal workplace is Miami; commuting expenses to Tampa HQ are reimbursable.","Agreements include one-year non-competition and 12-month non-solicitation restrictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345569,"accession_number":"0000950170-22-019317","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2022-10-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cryo-Cell annual meeting votes: all four directors elected, equity plan approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Portnoy elected with 3.97M for, 2.01M withhold; other directors similarly approved.","Ratification of WIPFLI LLC as auditor: 4.56M for, 129K against, 1.29M abstain.","Non-binding say-on-pay resolution passed: 3.55M for, 2.42M against.","Frequency vote: 2.97M preferred every 1 year, 2.77M every 3 years; board will adopt 1-year.","2022 Equity Incentive Plan approved: 3.54M for, 2.44M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362011,"accession_number":"0000950170-22-017696","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cryo-Cell sets 2022 annual meeting for Oct 3; record date Sept 2","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting scheduled October 3, 2022; record date for shareholders is September 2, 2022.","Stockholder proposals and director nominations must be submitted by September 2, 2022 per bylaws.","Public disclosure of meeting date made August 23, 2022 triggering 10-day submission window.","No other material events reported in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362010,"accession_number":"0000950170-22-017659","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cryo-Cell declares $0.90 special cash dividend payable Sept 9, 2022","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["One-time special cash dividend of $0.90 per share of common stock declared.","Shareholders of record as of close of business on September 2, 2022 are eligible.","Dividend expected to be paid on September 9, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362009,"accession_number":"0000950170-22-012926","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2022-07-22T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Cryo-Cell enters $18.96M credit facility with Susser Bank; term loan for NC building purchase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility of up to $10M and term loan of $8.96M with Susser Bank.","Term loan proceeds used to purchase commercial office building in Durham, North Carolina (previously disclosed).","RCF matures July 18, 2025; term loan matures July 18, 2032.","Interest at Base Rate plus 4.25% or SOFR plus 3.25% (floors of 5.5% and 4.5%, respectively).","Covenants: leverage ratio ≤3.50x, debt service coverage ≥1.25x; dividends restricted if default exists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399480,"accession_number":"0000950170-22-003951","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2022-03-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cryo-Cell buys $11.2M NC facility to launch ExtraVault biorepository service","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase price $11.2M for 56,000 sq ft building under construction in Durham, NC.","Facility to introduce ExtraVault biorepository service for biopharma and healthcare.","Initial earnest deposit of $200,000; closing subject to customary conditions.","Funding from cash on hand, operations, and additional financing.","ExtraVault plans cost-effective storage, inventory portal, and distribution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399479,"accession_number":"0000950170-22-002003","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryo-Cell reports FY2021 revenue $28.9M (-7% YoY), net income $2.1M (-42% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $28.9M, down 7% from $31.1M; processing/storage fees $28.4M vs $29.5M.","Net income $2.1M ($0.26 basic EPS) vs $3.6M ($0.48 basic EPS) in FY2020.","Public banking revenue fell to $376K from $727K; no licensee income vs $630K prior year.","Recorded $1.2M public bank inventory impairment and $782K gain on contingent consideration.","SG&A increased 2% while cost of sales decreased 7% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399478,"accession_number":"0000950170-22-000481","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2022-01-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cryo-Cell receives Nasdaq notice for audit committee non-compliance; cure period until Sept 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified that audit committee has only 2 independent members, needs 3 per Rule 5605.","Cure period: earlier of next annual meeting or September 20, 2022 (or March 21, 2022 if meeting before that).","Company must submit documentation evidencing compliance by the cure deadline.","Cryo-Cell states it is working diligently to regain compliance within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418466,"accession_number":"0001564590-21-060452","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cryo-Cell director Brian Sheehy resigns effective Dec 13, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Sheehy resigned from the Board on December 13, 2021.","Resignation did not result from any disagreement with the Company.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418465,"accession_number":"0001564590-21-051764","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2021-10-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cryo-Cell shareholders elect all five director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Harold Berger, David Portnoy, Mark Portnoy, Brian Sheehy, Daniel Mizrahi elected as directors.","WIPFLI LLC ratified as independent auditor for fiscal year ending Nov 30, 2021.","Non-binding advisory resolution on named executive officer compensation approved.","Director votes: 4.5M-5.1M for; auditor: 5.3M for; say-on-pay: 4.7M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418464,"accession_number":"0001564590-21-050957","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2021-10-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryo-Cell Q3 2021 revenue down 8% to $7.5M; net income $857K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.5M vs $8.1M YoY; processing/storage fees $7.3M, public banking $159K.","Net income $857K ($0.10 per share) vs $784K ($0.10) in Q3 2020.","Cost of sales +4%, SG&A +3% due to $167K for Cellular Therapies Institute and $131K Duke patent license expenses.","Recorded $325K decrease in fair value of contingent consideration liability for Cord:Use earn-out.","No guidance provided; company highlights transformation into cellular therapy company."],"consensus_eps_estimate":null,"consensus_eps_actual":0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":21569464.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436027,"accession_number":"0001564590-21-048617","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2021-09-22T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cryo-Cell appoints co-CEO Portnoy and Mizrahi to board; Oct 20 annual meeting set","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Gaines (retired) and Jonathan Wheeler (health reasons) resigned as directors effective Sept 17/20, 2021.","Board appointed Mark Portnoy (Co-CEO) and Daniel Mizrahi (CEO of Power Tech, S.A.) to fill vacancies effective Sept 20, 2021.","Annual stockholders' meeting fixed for October 20, 2021; record date September 20, 2021; proposal deadline September 22, 2021.","Press release highlights recent NASDAQ uplisting, though filing still lists OTCQB as trading symbol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436026,"accession_number":"0001564590-21-040910","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cryo-Cell signs new employment agreement with CIO Oleg Mikulinsky; $300K salary, $35K signing bonus","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective Aug 1, 2021, Cryo-Cell entered a 2-year employment agreement with CIO Oleg Mikulinsky.","Annual base salary of $300,000; discretionary bonus up to 25% of base salary.","One-time signing bonus of $35,000 in cash upon effective date.","Severance of 12 months base salary payable over 3 years for termination without cause or resignation with good reason.","Company will pay COBRA medical/dental premiums for up to 24 months post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436025,"accession_number":"0001564590-21-037044","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC","ticker":"CCEL","form_type":"8-K","filed_at":"2021-07-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryo-Cell Q2 fiscal 2021 revenue down 8% to $7.21M; net income rises to $1.17M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.21M, down 8% from $7.87M; processing/storage fees $7.16M.","Net income $1.17M ($0.15 basic EPS) vs $953K ($0.13) a year ago; net income up 23%.","Cost of sales decreased 10% and SG&A decreased 12% year-over-year, offsetting revenue decline.","Recorded $432K decrease in fair value of contingent consideration liability from Cord:Use earn-out; $240K amortization on Duke University license."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":14065812.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27306959.497058824,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}